Kobelt G, Jönsson B
Department of Orthopedics, University of Lund, Lund, Sweden.
Eur J Health Econ. 2008 Jan;8 Suppl 2:95-106. doi: 10.1007/s10198-007-0091-0.
Within the series of articles investigating the burden of rheumatoid arthritis (RA), this paper reviews the methods used for economic assessment of the RA treatments by HTA agencies and other bodies involved in cost-effectiveness analysis and the current status of the field. The overall methods, as well as the challenges, of cost-effectiveness analysis in RA are common to all chronic progressive diseases where much of the treatment benefit is delayed, while costs occur immediately. Also, as in all disabling diseases, much of the costs occur outside the health-care system, due to the rapid loss of work capacity and the need for informal care in the later stages of the disease. Thus, it is essential to adopt a long-term view and consider costs from the perspective of society, rather than the health-care service, to increase the relevance of the results for policy making.
在一系列关于类风湿性关节炎（RA）负担的文章中，本文回顾了卫生技术评估机构及其他参与成本效益分析的机构对RA治疗进行经济评估所使用的方法以及该领域的现状。RA成本效益分析的总体方法及挑战，对于所有治疗效益大多延迟而成本即刻产生的慢性进展性疾病来说都是共通的。此外，与所有致残性疾病一样，由于工作能力迅速丧失以及疾病后期需要非正式护理，大部分成本发生在医疗保健系统之外。因此，必须采取长远眼光，从社会而非医疗保健服务的角度考虑成本，以提高结果对政策制定的相关性。
